Exchange: NASDAQ·Updated 07:30 PM EDT
ALZN logo

ALZN Alzamend Neuro Inc

$1.66
$0.005
(0.30%)
Today
Closed $1.66
$0.00
(0.00%)
After Hours
Reported EarningsSep 16
Mkt Cap$8.01M
Vol242,129.00

About ALZN

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.
45

Neutral Sentiment

How do you feel about ALZN?

Advertisement|Remove ads.